EHA 2015 highlights

Share :
Published: 17 Jun 2015
Views: 3263
Rating:
Save
Peter Goodwin - ecancer reporter

For busy professionals who want to catch up on the latest in haematology, ecancertv reporter Peter Goodwin summarises some of the key topics from EHA 2015.

- First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia
   news story, press conference, video interview
 

- A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia
   news story, press conference, video interview
 

- Discontinuation of Tyrosine Kinase inhibitors in chronic myeloid leukaemia 
   Abstract
 

- Favourable prognosis for NMP1 mutation carrying elderly AML patients
  Abstract

EHA 2015

EHA 2015 highlights

Peter Goodwin - ecancer reporter


Here at the European Haematology Association meeting in Vienna we’ve been hearing about newly diagnosed acute myeloid leukaemia and how you can now go beyond chemotherapy with sorafenib to increase relapse free survival. For patients with relapsed or refractory chronic lymphocytic leukaemia there could now be an option with the drug venetoclax which targets BCL-2. This apparently has achieved deep responses, according to research from Australia.

In chronic myeloid leukaemia light has been thrown on whether and when you can discontinue TKI therapy. It seems to be that deep molecular responses are what you need to look for. And we have news from the United Kingdom about a mutation many of us have that can cause leukaemia, not in the young but usually in the old and dependent on the blood making environment.

So do stay with ecancer.tv here at the European Haematology Association in Vienna for expert interviews, round table discussions and all the latest news in haematology oncology.